Wealth Enhancement Advisory Services LLC Sells 3,780 Shares of Humana Inc. $HUM

Key Points

• Wealth Enhancement Advisory Services LLC decreased its holdings in Humana Inc. by 24%, selling 3,780 shares in the second quarter, leaving it with 11,954 shares valued at approximately $2.87 million.
• Humana Inc.'s recent quarterly earnings report showed an EPS of $6.27, which missed analyst expectations by 5 cents, despite revenue surpassing estimates at $32.39 billion.
• The company declared a quarterly dividend of $0.885 per share, indicating a 1.4% dividend yield and a payout ratio of 27.17%.

Wealth Enhancement Advisory Services LLC cut its holdings in Humana Inc. (NYSE:HUM - Free Report) by 24.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,954 shares of the insurance provider's stock after selling 3,780 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Humana were worth $2,865,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after purchasing an additional 1,143,662 shares in the last quarter. Dodge & Cox raised its stake in Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock valued at $2,845,830,000 after purchasing an additional 557,175 shares during the last quarter. Pzena Investment Management LLC lifted its position in Humana by 6.1% in the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock valued at $1,013,133,000 after buying an additional 219,541 shares during the last quarter. Davis Selected Advisers boosted its holdings in Humana by 3.3% during the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock valued at $616,873,000 after acquiring an additional 74,434 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in shares of Humana by 1.6% in the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider's stock valued at $327,293,000 after buying an additional 19,613 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of Humana stock opened at $254.72 on Friday. The stock has a market cap of $30.64 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.50 and a beta of 0.44. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $324.38. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $271.91 and a 200-day simple moving average of $257.37.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. Humana's payout ratio is presently 27.17%.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of recent research reports. Evercore ISI assumed coverage on Humana in a report on Monday, September 22nd. They issued an "in-line" rating and a $295.00 target price on the stock. Bank of America upped their price target on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Truist Financial dropped their price target on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th. Barclays increased their target price on Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a research note on Friday, September 5th. Finally, Wells Fargo & Company lowered their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Seven research analysts have rated the stock with a Buy rating and seventeen have given a Hold rating to the stock. Based on data from MarketBeat.com, Humana has a consensus rating of "Hold" and a consensus target price of $289.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.